ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022 The Addition of Inotuzumab Ozogamicin to Hyper-CVAD + Blinatumomab to Improve Outcomes in Pts With Newly Diagnosed B-ALL: Updated Results From a Phase II Study
By
ASH 2022 Conference Coverage
FEATURING
Nicholas Short
By
ASH 2022 Conference Coverage
FEATURING
Nicholas Short
138 views
January 5, 2023
Login to view comments.
Click here to Login
Leukemia